Denali Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Denali Therapeutics has a total shareholder equity of $1.4B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $1.5B and $115.5M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$896.04m |
| Equity | US$1.39b |
| Total liabilities | US$115.51m |
| Total assets | US$1.50b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: D2NL34's short term assets ($928.4M) exceed its short term liabilities ($74.5M).
Long Term Liabilities: D2NL34's short term assets ($928.4M) exceed its long term liabilities ($41.0M).
Debt to Equity History and Analysis
Debt Level: D2NL34 is debt free.
Reducing Debt: D2NL34 has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: D2NL34 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: D2NL34 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 28.7% each year